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Abstract: Lipid-soluble micronutrients may be beneficial to non-alcoholic fatty liver disease due
to their important roles in metabolism and maintaining tissue functions. Utilizing 2017–2018 Na-
tional Health and Nutrition Examination Survey, this study examined the potential overall and
race/ethnicity-specific (black, Hispanic and white) associations of dietary lipid-soluble micronu-
trients (α-tocopherol, retinol, vitamin D, β-carotene and total carotenoids) with hepatic steatosis.
The analysis included 4376 adults (1037 blacks, 981 Hispanics, 1549 whites) aged ≥20 years who
completed the transient elastography examination with dietary data available. Odds ratios (OR)
and 95% confidence intervals (95%CI) were estimated using logistic regressions. The age-adjusted
prevalence of steatosis was 20.9% for blacks, 34.0% for Hispanics and 28.7% for whites. Overall,
dietary α-tocopherol was inversely associated with steatosis (highest vs. lowest quartile: OR = 0.51,
95%CI = 0.35–0.74, Ptrend = 0.0003). The associations remained significant among blacks (highest
vs. lowest tertile: OR = 0.45, 95%CI = 0.26–0.77, Ptrend = 0.002) and whites (highest vs. lowest
tertile: OR = 0.56, 95%CI = 0.33–0.94, Ptrend = 0.02). Higher α-tocopherol intake was associated with
lower odds of steatosis among all (Ptrend = 0.016) and black participants (Ptrend = 0.003) classified
as never/rare/occasional alcohol drinkers. There was a trend suggesting higher β-carotene intake
with lower odds of steatosis (Ptrend = 0.01). Our results suggest potential protective effects of dietary
vitamin E as α-tocopherol on steatosis particularly among blacks.
Keywords: α-tocopherol; retinol; vitamin D; β-carotene; carotenoids; hepatic steatosis; race/ethnicity
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is becoming the most common liver disease
in the United States (U.S.) [1–4], encompassing a broad spectrum of liver injury including
isolated storage of fat in the liver, steatosis, and severe steatohepatitis that can progress
to fibrosis, cirrhosis, liver failure or even liver cancer [2]. The etiology of NAFLD remains
poorly understood and there is no accepted pharmaceutical or surgical treatment [1,2].
Therefore, modifications of diet and other lifestyle factors may play important roles in
preventing the development of NAFLD as well as progression to more severe conditions
once disease has developed.
Although the pathophysiology of NAFLD is complex, it has been suggested that
insulin resistance and oxidative stress are likely significant contributing factors to the
pathogenesis of NAFLD in all age groups [5–7]. Lipid-soluble micronutrients, such as
carotenoids, retinol (vitamin A), vitamin D, and tocopherols (forms of vitamin E) play criti-
cal roles in metabolism and the maintenance of tissue functions [8–11]. They may also act as
antioxidants neutralizing free radicals and thereby reducing oxidative stress [8,9]. Several
studies have assessed the relationships between dietary factors including dietary lipid-
soluble micronutrient intake and NAFLD in recent years [12–15]. For example, α-tocopherol
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(the predominant form of vitamin E) can limit membrane injury precipitated by reactive
oxygen species and is considered as a promising antioxidant for NAFLD prevention [12].
Several observational studies have reported lower dietary or circulating α-tocopherol levels
were observed in patients with NAFLD compared to normal controls [16,17]. However,
randomized controlled trials showed conflicting results on the efficacy of vitamin E (as
α-tocopherol) among patients with NAFLD [18–20]. Likewise, vitamin D deficiency is
common in patients with liver diseases [21]. Epidemiological evidence shows patients
with NAFLD had marked decreases in serum vitamin D levels compared to healthy in-
dividuals [22–25]. Similar to α-tocopherol, conflicting results have been reported from
clinical trials examining the effects of vitamin D supplementation on the progression and
severity of NAFLD [10,11]. Currently there are no solid epidemiological data on relations
between dietary vitamin D intake and NAFLD. With respect to carotenoids, researchers
found the odds of NAFLD was significantly reduced for the highest quartiles of intake of
carotenoids (e.g., α-carotene, β-carotene, β-cryptoxanthin, and lutein/zeaxanthin) com-
pared to the lowest. They also found serum levels of total carotenoids were inversely
associated with NAFLD prevalence [13]. In addition, significantly decreased levels of circu-
lating carotenoids such as α-carotene, β-carotene, lycopene, lutein and zeaxanthin were
observed in patients with non-alcoholic steatohepatitis relative to normal controls [16].
Prior studies have suggested racial/ethnic differences in prevalence of NAFLD [3,26,27].
Hispanics, particularly experience the highest incidence and prevalence of NAFLD [3,28]
and continuous annual increases in NAFLD-related mortality [29]. Although blacks had
lower prevalence of NAFLD compared to whites and Hispanics [3,26], for those diag-
nosed with NAFLD, advanced fibrosis was nevertheless the highest for blacks among
all racial/ethnic groups [3]. The associations between lipid-soluble micronutrients from
diet or in circulation with health and diseases may differ among racial/ethnic groups.
Our previous study using a nationally representative sample suggests there might be
race/ethnicity-specific thresholds for the associations with all-cause or cause-specific mor-
tality for serum levels of total vitamin E, α-tocopherol and total carotenoids [30]. To our
knowledge, no studies have assessed race/ethnicity-specific relationships between lipid-
soluble micronutrients and NAFLD using a nationally representative sample. Therefore,
utilizing 2017–2018 National Health and Nutrition Examination Survey (NHANES), a
nationally representative sample, the current study examined the potential overall and
race/ethnicity-specific (black, Hispanic and white) associations of dietary intake of lipid-
soluble micronutrients including α-tocopherol, retinol, vitamin D, β-carotene and total
carotenoids with hepatic steatosis among adults in the United States. Additionally, we also
investigated whether the above associations, if present varied by alcohol drinking habits.
2. Materials and Methods
2.1. Study Population
NHANES is an ongoing program of studies intended to assess the health and nu-
tritional status of approximately 5000 adults and children in the United States each year.
NHANES uses a complex, multistage, probability sampling design to select participants
who are geographically dispersed and representative of the civilian, noninstitutionalized
US population [31].
The 2017–2018 data were used as the liver ultrasound transient elastography were only
performed in 2017–2018 NHANES examinations (besides NHANES III) to provide objective
measures for two important liver disease manifestations: hepatic steatosis (fat in the liver)
and fibrosis (scarring in the liver) [31]. We only used the measures for steatosis since fibrosis
was not of interest in our study. The current analyses included participants aged 20 years or
above. We further excluded participants who were pregnant or breastfeeding, participants
whose dietary recalls were not reliable or meeting the minimum criteria, and participants
with missing data on dietary intake (total energy, dietary lipid-soluble micronutrients),
liver ultrasound transient elastography examination, education and body mass index (BMI).
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A total of 4376 participants were involved in the final analytic sample including 1037 black,
981 Hispanics and 1549 white participants.
2.2. Dietary Intake of Lipid-Soluble Micronutrients
The NHANES dietary interview component gathers detailed dietary intake from
participants. On two separate occasions, participants reported their food and beverage
intake over the past 24 h using the USDA’s Automated Multiple-Pass Method [32,33]. The
two 24-h recalls were conducted in NHANES 2017 to 2018. The first dietary recall was
collected in person by trained interviewers in NHANES Mobile Exam Center (MEC) and
the second dietary recall was completed by trained interviewers via telephone 3–10 days
after the MEC interview [32]. The data collected from each participant’s two 24-h recall
interviews were coded and linked to a database of foods and beverages and their nu-
trient compositions. The database was used to estimate the types and amounts of food
and beverages (including water) consumed, as well as to estimate energy, nutrients, and
other components from those food and beverage items. For 2017–2018 NHANES cycle,
dietary data were available on the following lipid-soluble micronutrients: α-tocopherol
(the predominant form of vitamin E), retinol (vitamin A), vitamin D (vitamin D2 + vitamin
D3), α-carotene, β-carotene, β-cryptoxanthin, lycopene, and lutein/zeaxanthin (combined
measure). This paper concentrated on α-tocopherol, retinol, vitamin D, β-carotene (a
major pro-vitamin A carotenoid) and total carotenoids (dietary total intake of α-carotene,
β-carotene, β-cryptoxanthin, lycopene, and lutein/zeaxanthin). The current study used the
first dietary recall interview because it was collected in person by trained interviewers in
NHANES MEC. However, correlations between intakes of individual dietary lipid-soluble
micronutrients from the first and second recall interviews were performed and they were
significantly and positively correlated (ps < 0.0001).
2.3. Ascertainment of Outcomes
The elastography measurements were obtained in the NHANES MEC using FibroScan®
(Echosens, Cambridge, MA, USA). The device has incorporated a novel physical parameter,
controlled attenuation parameter (CAPTM) (Echosens, Cambridge, MA, USA), which mea-
sures the ultrasound attenuation related to the presence of hepatic steatosis. All participants
were asked to fast at least 3 h before the examination. The FibroScan examination procedure
has been detailed in the NHANES liver Utrasound Transient Elastography Procedureds
manual [34]. The above is considered as a reliable, non-invasive method and the accuracy
of CAPTM measurement for the detection of steatosis against biopsy has been reported
in a few studies with sensitivity, specificity, and area under ROC curve being 76–79%,
71–79% and ≥80%, respectively [35–37]. A recent prospective study analyzed, assessed,
and reported optimal CAP cutoff values to define steatosis grade/stage (S1–S3, steatosis
grade/stage was initially defined by histological assessment) [38]. A threshold value of
302 dB/m was selected to define participants with steatosis (S > S1, 5% steatosis) based on
the aforementioned study [38].
2.4. Statistical Analyses
The “Survey” procedure in SAS 9.4 software (SAS Institute, Cary, NC, USA) was used
to estimate variance after incorporating the complex, multistage, clustered probability sam-
pling design of the NHANES [39]. Characteristics and covariates were compared between
those with and without steatosis using Rao–Scott chi-square test for categorical variables
and Student’s t-test for continuous variables. The age-adjusted prevalence of steatosis was
estimated, stratified by age groups using the 2000 US Census as the standard population.
Logistic regressions (proc survey logistic) were used to estimate odds ratios (OR) and
95% confidence intervals (95%CI) for associations between dietary intakes of lipid-soluble
micronutrients and steatosis outcomes. For all participants (N = 4376), dietary levels of
lipid-soluble micronutrients (α-tocopherol, retinol, vitamin D, β-carotene, total carotenoids)
were categorized into quartiles using the lowest category as the reference. Two models were
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estimated: Model 1 was adjusted for age (continuous), sex, race/ethnicity (black, Hispanic,
white, or Asian/other), education (less than high school, high school/some college, or
college graduate), body mass index (BMI, continuous), smoking status (never, former, or
current smoker) and daily total energy intake (continuous). Model 2 included the covariates
in Model 1 and was further adjusted for alcohol drinking habits (never/rarely (never or
1 to 2 times in the last year), occasionally (3 to 11 times in the last year or once/month),
sometimes (2 to 3 times/month or 1–2 times a week) or frequently (3 to 4 times a week or
nearly every day or every day)), history of diabetes (yes or no) and high blood pressure
(yes or no), hepatitis B virus (HBV) infection status (no infection, current/past infection,
or not clear) and hepatitis C virus (HCV) infection status (no infection or current/past
infection). The above analyses were repeated in three racial/ethnic groups (black, Hispanic,
and white). Due to relatively small sample size for blacks, (N = 1037) and Hispanics
(N = 981), dietary levels of lipid-soluble micronutrients were categorized into tertiles using
the lowest tertile as the reference category. We used race/ethnicity-specific cut-points to
define tertiles within the individual racial/ethnic groups. Similar to the overall analyses
for all participants, we performed two models (Model 1 and Model 2) and results from
the full model (Model 2) were reported. We did not perform analyses among Asians
and others because of limited number of participants in these two groups. Participants
were also asked about supplement use for the same 24-h period and supplement intake of
vitamin D (vitamin D2 + vitamin D3), lycopene and lutein/zeaxanthin were available. For
dietary vitamin D intake, we included intakes of vitamin D from both diet and supplement.
Sensitivity analyses were performed after including supplement intake of lycopene and
lutein/zeaxanthin into dietary consumption of total carotenoids.
The analyses for overall and race/ethnicity-specific relations stratified by participants’
alcohol drinking habits were performed by Logistic regression models (proc survey lo-
gistic). We used the question “Past 12 months how often have alcohol drink” to define
participants alcohol drinking habits. We combined participants’ responses into two cate-
gories: never/rarely/occasionally vs. sometimes/frequently. A participant was classified
as a never/rare/occasional alcohol drinker if the participant had 0–12 times/drinks in
the past year. All statistical analyses were conducted in SAS 9.4 software (SAS Institute,
Cary, NC, USA). All tests were two-sided, and p < 0.05 was used as the critical value for
statistical significance.
3. Results
The age-adjusted prevalence of steatosis was 28.3% for overall population, 20.9% for
blacks, 34.0% for Hispanics and 28.7% for whites. Table 1 summarizes race/ethnicity-
specific characteristics by steatosis status. Among all three racial/ethnic groups (black,
Hispanic and white), participants with steatosis were older and obese with a history of
diabetes and high blood pressure and less likely to have a college degree compared to those
without the condition (ps < 0.05). For Hispanics and whites, higher proportions of partici-
pants with steatosis were men and former smokers (ps < 0.05). Similar trends were observed
among blacks for the aforementioned characteristics although the differences were not
statistically significant. Blood levels of two liver enzymes, aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) and high-sensitive C-reactive protein (HS-CRP,
indicator for systemic inflammation) were significantly higher among participants with
steatosis than individuals without the disease for all racial/ethnic groups (ps < 0.05) except
for AST among blacks. For participants with steatosis, Hispanics appeared to have the
highest mean ALT and AST values. In contrast, HS-CRP levels were higher among blacks
compared to other racial/ethnic groups (black: 7.7 ± 0.5 mg/L; Hispanic: 4.6 ± 0.3 mg/L;
white: 5.5 ± 0.4 mg/L). With respect to dietary intake, black participants with steatosis
had significantly lower intake of α-tocopherol (8.1 ± 0.4 mg/day vs. 8.9 ± 0.3 mg/day,
p = 0.03) and total carotenoids (7385 ± 732 µg/day vs. 9261 ± 445 µg/day, p = 0.005) com-
pared to their counterparts without the condition. Among Hispanics a significantly lower
percentage of participants with steatosis (45.9%) reported taking any supplements relative
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to participants without the condition (51.7%, p = 0.02). Additionally, Hispanics had the
lowest dietary vitamin D intake (Hispanic: 12.6 ± 0.7 µg/day vs. white: 27.7 ± 3.4 µg/day;
p < 0.0001) followed by blacks (22.1 ± 9.0 µg/day). Dietary α-tocopherol intake was
lower in blacks (8.9 ± 0.3 mg/day) than that in whites (9.6 ± 0.3 mg/day) and Hispanics
(9.3 ± 0.3 mg/day) although the differences were not statistically significant.
The overall associations of dietary lipid-soluble micronutrients with steatosis for all
participants (N = 4376) are shown in Table 2. Dietary α-tocopherol intake was inversely
associated with steatosis in both Model 1 (Ptrent = 0.002) and Model 2 (fully adjusted model;
Ptrent = 0.0003). The odds of steatosis was almost reduced to half comparing the highest to
the lowest quartile of α-tocopherol intake in Model 2 (OR = 0.51, 95%CI = 0.35–0.74). For
β-carotene, although there was a trend (Ptrent = 0.03 for Model 1, Ptrent = 0.01 for Model 2)
suggesting higher β-carotene intake was associated with lower odds of steatosis, none of
the ORs and 95%CIs were significant when comparing higher quartiles (Quartiles 2 to 4) to
the lowest quartile of β-carotene intake. No significant overall associations were observed
for dietary retinol, vitamin D or total carotenoids intake with steatosis (ps > 0.05).
Table 3 demonstrates the race/ethnicity-specific associations of dietary lipid-soluble
micronutrients with steatosis. Dietary α-tocopherol intake was inversely associated with
steatosis among both blacks (Ptrent = 0.002) and whites (Ptrent = 0.02) in the fully ad-
justed model. The odds of having steatosis was approximately 55% lower among blacks
(OR = 0.45, 95%CI = 0.26–0.77) and 44% lower among whites (OR = 0.56, 95%CI = 0.33–0.94)
for the highest versus the lowest tertile of α-tocopherol intake. No significant associa-
tion between dietary α-tocopherol intake and steatosis was observed among Hispanics.
However, the odds of having steatosis was significantly higher for the second (Tertile 2)
against the lowest tertile of α-tocopherol intake (OR = 1.57, 95%CI = 1.04–2.38) among
Hispanics. No significant associations of dietary retinol, vitamin D, β-carotene or total
carotenoids with steatosis were observed among the individual racial/ethnic groups al-
though the odds of steatosis were significantly higher for the second against the lowest
tertile for β-carotene (OR = 1.60, 95%CI = 1.08–2.39) among whites and for total carotenoids
(OR = 1.49, 95%CI = 1.06–2.09) among blacks. Results did not change materially after in-
cluding supplement intake of lycopene and lutein/zeaxanthin (the two carotenoids in the
current study that had supplement intake information) into the intake of total carotenoids.
Further adjusting for dietary supplement intake (yes or no) did not significantly change
the results.
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Table 1. Characteristics of Study Participants by Hepatic Steatosis Status and Race/Ethnicity.
Characteristics Black Hispanic White
All Non-Steatosis Steatosis p a All Non-Steatosis Steatosis p a All Non-Steatosis Steatosis p a
N 1037 804 233 981 626 355 1549 1055 494
Age (y) 45.8 ± 0.6 44.6 ± 0.7 50.4 ± 1.1 0.0001 43.0 ± 0.9 41.7 ± 1.0 45.7 ± 1.1 0.0002 50.3± 0.9 49.0± 1.0 53.6± 0.9 0.0001
Sex, (%) 0.39 0.001 <0.0001
Men 47.4 46.2 51.7 51.0 46.6 59.4 49.6 44.6 62.0
Women 52.6 53.8 48.3 50.0 53.4 40.6 50.4 55.4 38.0
Education (%) 0.04 0.01 0.0003
Below high school 11.5 11.1 12.9 26.8 28.1 24.3 6.1 6.0 6.6
High school/some college 67.4 66.1 72.2 57.3 54.3 63.2 59.0 56.5 65.3
College graduate 21.1 22.8 14.9 15.9 17.7 12.5 34.9 37.5 28.1
Body mass index (kg/m2) 31.1 ± 0.3 29.3 ± 0.2 38.1 ± 0.6 <0.0001 30.4 ± 0.3 28.4 ± 0.4 34.3 ± 0.6 <0.0001 29.6 ± 0.4 29.0 ± 0.3 35.2 ± 0.6 <0.0001
Obese (≥30 kg/m2) (%) 49.1 38.6 88.7 <0.0001 45.7 32.1 72.0 <0.0001 42.5 29.0 75.9 <0.0001
Smoke status (%) 0.08 0.03 <0.0001
Never 62.8 64.6 55.8 64.9 67.5 59.9 53.9 56.6 47.2
Former 16.0 14.5 21.7 22.4 19.4 28.2 28.6 25.6 36.2
Current 21.2 20.9 22.5 12.7 13.1 11.9 17.5 17.8 16.6
Alcohol drinking habits in
past 12 months (%) 0.42 0.33 0.07
Never/rarely 34.8 33.7 38.4 33.8 34.3 32.8 30.6 28.1 37.0
Occasionally 24.4 24.2 25.4 22.6 23.1 21.4 21.7 21.2 22.8
Sometimes 27.0 27.8 24.1 34.9 35.3 34.1 31.8 33.7 27.0
Frequently 13.8 14.3 12.1 8.7 7.3 11.5 15.9 17.0 13.2
Diabetes (%) 14.8 11.1 28.8 <0.0001 12.0 7.5 20.8 <0.0001 13.4 7.2 29.0 <0.0001
High blood pressure (%) 40.4 35.2 59.4 <0.0001 22.1 17.3 31.5 <0.0001 33.1 25.7 51.8 <0.0001
HBV infection (%) b 6.5 6.1 8.0 0.69 2.8 2.1 4.2 0.18 2.7 2.1 3.9 0.11
HCV infection (%) c 2.8 2.7 3.2 0.34 1.7 1.3 2.4 0.12 3.2 3.5 2.3 0.50
AST (IU/L) d 21.5 ± 0.4 21.1 ± 0.6 23.0 ± 0.9 0.08 22.6 ± 0.6 20.9 ± 0.4 26.0 ± 1.2 <0.0001 22.4 ± 0.5 21.7 ± 0.6 24.2 ± 1.0 <0.0001
ALT (IU/L) e 20.1 ± 0.6 18.6 ± 0.7 25.6 ± 0.9 <0.0001 25.9 ± 0.7 22.3 ± 0.7 32.8 ± 1.4 <0.0001 23.2 ± 0.7 20.7 ± 0.6 29.5 ± 1.6 <0.0001
HS-CRP (mg/L) f 4.6 ± 0.1 3.8 ± 0.2 7.7 ± 0.5 <0.0001 3.8 ± 0.3 3.4 ± 0.3 4.6 ± 0.3 0.002 3.7 ± 0.2 3.0 ± 0.3 5.5 ± 0.4 <0.0001
Dietary intake
Total energy (kcal) 2126 ± 33 2127 ± 40 2121 ± 86 0.84 2233 ± 31 2186 ± 39 2324± 65 0.40 2209 ± 27 2172 ± 38 2302 ± 47 0.53
α-Tocopherol (mg/day) 8.9 ± 0.3 8.9 ± 0.3 8.1 ± 0.4 0.03 9.3 ± 0.3 9.4 ± 0.4 9.1 ± 0.3 0.34 9.6 ± 0.3 9.8 ± 0.3 8.9 ± 0.3 0.16
Retinol (µg/day) 343 ± 17 345 ± 21 336 ± 26 0.42 379 ± 19 375 ± 24 387 ± 26 0.71 444 ± 9 448 ± 11 436 ± 25 0.64
Vitamin D (µg/day) g 22.1 ± 7.0 22.0 ± 8.6 22.6 ± 7.3 0.45 12.6 ± 0.7 13.1 ± 0.7 11.5 ± 1.4 0.61 27.2 ± 3.4 27.0 ± 4.7 27.7 ± 3.4 0.94
β-Carotene (µg/day) 2328 ± 242 2463 ± 282 1821 ± 230 0.48 2508 ± 235 2659 ± 269 2215 ± 308 0.24 2429 ± 200 2452 ± 217 2371 ± 340 0.53
Tot carotenoid
(µg/day) h 8868 ± 413 9261 ± 445 7385 ± 732 0.005 10743 ± 745 11036 ± 942 10175 ± 888 0.68 9181 ± 403 9344 ± 509 8774 ± 724 0.42
Take supplement (%) 47.4 46.0 52.5 0.28 49.7 51.7 45.9 0.02 61.1 61.7 59.6 0.47
Note: Values are presented as weighted mean ± SE and weighted percentage (%). a p values for differences between participants with steatosis and participants without steatosis within the individual
racial/ethnic groups using t tests for continuous variables and chi-squared test for categorical variables; b HBV = hepatitis B virus; c HCV = hepatitis C virus; d AST = Aspartate aminotransferase; e ALT = Alanine
aminotransferase; f HS-CRP = high-sensitive C-reactive protein; g Daily vitamin D intake includes vitamin D intake from diet and supplement; h Tot carotenoids = total carotenoids.
Biomedicines 2021, 9, 1093 7 of 17
Table 2. Overall Odds Ratio and 95% Confidence Interval for Hepatic Steatosis by Quartiles (Q1-Q4) of Dietary Micronutrients.
Micronutrients
OR (95% CI) a
Ptrend a
Q1 Q2 Q3 Q4
α-Tocopherol (mg/day)
Quartile range <4.4 4.4–6.9 6.9–10.5 ≥10.5
Number of participants 964 1031 1113 1268
Number of cases 293 299 344 361
Model 1 b 1.00 0.76 (0.58–0.99) 0.81 (0.54–1.21) 0.54 (0.39–0.76) 0.002
Model 2 c 1.00 0.81 (0.60–1.10) 0.83 (0.55–1.26) 0.51 (0.35–0.74) 0.0003
Retinol (µg/day)
Quartile range <161.0 161.0–333.0 333.0–561.0 ≥561.0
Number of participants 1268 1118 1027 963
Number of cases 360 335 307 295
Model 1 b 1.00 1.04 (0.75–1.44) 0.74 (0.50–1.11) 0.88 (0.54–1.46) 0.53
Model 2 c 1.00 1.00 (0.71–1.42) 0.73 (0.48–1.09) 0.86 (0.52–1.44) 0.51
Vitamin D (µg/day) d
Quartile range <1.7 1.7–4.8 4.8–13.3 ≥13.3
Number of participants 1179 1053 809 1335
Number of cases 320 304 258 415
Model 1 b 1.00 0.96 (0.71–1.31) 1.00 (0.70–1.45) 1.09 (0.78–1.54) 0.41
Model 2 c 1.00 0.93 (0.67–1.30) 0.98 (0.67–1.45) 0.99 (0.69–1.43) 0.87
β-Carotene (µg/day)
Quartile range <217.0 217.0–615.0 615.0–1924.5 ≥1924.5
Number of participants 857 995 1202 1322
Number of cases 243 326 378 350
Model 1 b 1.00 1.08 (0.81–1.45) 1.14 (0.86–1.53) 0.85 (0.63–1.15) 0.03
Model 2 c 1.00 1.16 (0.87–1.56) 1.20 (0.86–1.66) 0.87 (0.65–1.16) 0.01
Total Carotenoids (µg/day)
Quartile range <1429.5 1429.5–4380.5 4380.5–10563.0 ≥10563.0
Number of participants 935 1039 1138 1264
Number of cases 289 296 344 368
Model 1 b 1.00 0.92 (0.64–1.32) 0.87 (0.56–1.36) 0.96 (0.66–1.39) 0.93
Model 2 c 1.00 1.00 (0.69–1.45) 0.86 (0.52–1.43) 0.99 (0.69–1.43) 0.91
a Odds ratio (OR), 95 confidence interval (95% CI) and Ptrend values were estimated using logistic regression (Proc Survey Logistic); b Model
1 was adjusted for age, race/ethnicity, sex, body mass index, education, smoking status and total energy intake; c Model 2 was adjusted
for covariates in Model 1 and was additionally adjusted for alcohol drink habits, history of diabetes, history of hypertension, Hepatitis B
infection status and Hepatitis C infection status; d Daily vitamin D intake includes vitamin D intake from diet and supplement.
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Table 3. Race/Ethnicity-Specific Odds Ratio and 95% Confidence Interval for Hepatic Steatosis by Tertles (T1-T3) of Dietary Micronutrients.
Micronutrients Black Hispanic White
T1 T2 T3 T1 T2 T3 T1 T2 T3
α-Tocopherol (mg/day)
Tertile range <5.3 5.3–9.5 ≥9.5 <5.6 5.6–10.3 ≥10.3 <6.1 6.1–10.2 ≥10.2
Participants (N) 347 331 359 343 338 300 574 481 494
Cases (N) 83 78 72 123 124 108 182 157 155
OR (95% CI) a 1.00 0.96 (0.56–1.64) 0.45 (0.26–0.77) 1.00 1.57 (1.04–2.38) 1.23 (0.81–1.88) 1.00 0.99 (0.67–1.47) 0.56 (0.33–0.94)
Ptrend a = 0.002 Ptrend a = 0.59 Ptrend a = 0.02
Retinol (µg/day)
Tertile range <135.2 135.2–364.2 ≥364.2 <182.5 182.5–427.8 ≥427.8 <246.2 246.2–491.2 ≥491.2
Participants (N) 341 338 358 319 344 318 505 482 562
Cases (N) 67 91 75 117 119 119 158 156 180
OR (95% CI) a 1.00 1.20 (0.83–1.73) 0.94 (0.48–1.84) 1.00 0.88 (0.60–1.34) 1.20 (0.66–2.22) 1.00 0.73 (0.42–1.27) 0.77 (0.40–1.50)
Ptrend a = 0.75 Ptrend a = 0.47 Ptrend a = 0.52
Vitamin D (µg/day) b
Tertile range <1.5 1.5–6.7 ≥6.7 <1.9 1.9–6.2 ≥6.2 <2.9 2.9–15.9 ≥15.9
Participants (N) 319 344 374 301 317 363 489 517 543
Cases (N) 57 83 93 107 122 126 154 170 170
OR (95% CI) a 1.00 1.03 (0.72–1.47) 0.99 (0.53–1.83) 1.00 1.03 (0.57–1.86) 0.86 (0.55–1.36) 1.00 0.96 (0.64–1.42) 0.91 (0.57–1.45)
Ptrend a = 0.93 Ptrend a = 0.37 Ptrend a = 0.68
β-Carotene (µg/day)
Tertile range <333.1 333.1–1254.2 ≥1254.2 <554.8 554.8–1836.6 ≥1836.6 <411.1 411.1–1600.6 ≥1600.6
Participants (N) 348 328 361 313 332 336 567 499 483
Cases (N) 69 89 75 116 124 115 184 170 140
OR (95% CI) a 1.00 1.39 (0.94–2.07) 1.07 (0.59–1.95) 1.00 0.88 (0.54–1.45) 0.74 (0.51–1.07) 1.00 1.60 (1.08–2.39) 0.99 (0.75–1.31)
Ptrend a = 0.77 Ptrend a = 0.11 Ptrend a = 0.22
Total carotenoids (µg/day)
Tertile range <2009.8 2009.8–7732.4 ≥7732.4 <3464.6 3464.6–10075.0 ≥10075.0 3005.4 3005.4–9489.2 ≥9489.2
Participants (N) 352 338 347 340 329 312 562 508 479
Cases (N) 72 90 71 129 114 112 183 157 154
OR (95% CI) a 1.00 1.49 (1.06–2.09) 1.08 (0.60–1.93) 1.00 0.84 (0.57–1.23) 0.90 (0.48–1.69) 1.00 0.96 (0.52–1.77) 1.17 (0.67–2.03)
Ptrend a = 0.77 Ptrend a = 0.83 Ptrend a = 0.53
a Odds ratio (OR), 95% confidence interval (95% CI) and Ptrend values were estimated by logistic regression (Proc Survey Logistic). Analyses were adjusted for age, sex, education, body mass index, smoking
status, total energy intake, alcohol drinking habits, hepatitis B virus infection, hepatitis C virus infection, history of diabetes and history of high blood pressure; b Daily vitamin D intake includes vitamin D intake
from diet and supplement.
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The overall and race/ethnicity-specific associations between dietary micronutrients
levels and steatosis stratified by alcohol drinking habits (never/rarely/occasionally vs.
sometimes/frequently) are shown in Table 4. For the overall population, higher α-tocopherol
intake was associated with reduced odds of steatosis among participants who were
characterized as never/rare/occasional drinkers (the highest quartile vs. the lowest
quartile: OR = 0.49, 95%CI = 0.27–0.89; Ptrent = 0.016). A similar but weaker trend be-
tween α-tocopherol intake and steatosis was found among participants who were some-
times/frequent alcohol drinkers (Ptrend = 0.06). Also, there was a trend (Ptrent = 0.007)
suggesting an inverse association between β-carotene intake and odds of steatosis among
never/rare/occasional drinkers although odds and 95%CIs for the higher quartiles against
the lowest were not statistically significant. In terms of race/ethnicity-specific associations,
dietary α-tocopherol intake was inversely associated with steatosis (Ptrend = 0.003) among
blacks who never, rarely or occasionally drank alcohol. There was approximately 63% re-
duction in odds of having steatosis for the highest versus the lowest tertile of α-tocopherol
intake (OR = 0.37; 95%CI = 0.18–0.73). Although not statistically significant, a similar
trend showing increased α-tocopherol intake with lower odds of steatosis was observed
among white participants who were sometimes/frequent alcohol drinkers (Ptrend = 0.09).
In addition, among whites who were never/rare/occasional drinkers, there appeared to
be an inverse trend between β-carotene intake and odds of steatosis (Ptrend = 0.01) but the
odds of the disease was higher for the second versus the lowest tertile of β-carotene intake
(OR = 1.81, 95%CI = 1.04–3.17). For Hispanics classified as sometimes/frequent drinkers,
the odds of steatosis was higher for the second tertile against the lowest of α-tocopherol
intake (OR = 2.62, 95%CI = 1.17–5.86). No significant associations of dietary intakes of
retinol, vitamin D or total carotenoids with steatosis were observed after stratification for
alcohol drinking habits except for a borderline, non-statistically significant trend suggest-
ing higher vitamin D intake with lower odds of steatosis among Hispanics classified as
sometimes/frequent alcohol drinkers (Ptrend = 0.08).
Table 4. Overall and Race/Ethnicity-Specific Associations of Dietary Micronutrients with Hepatic Steatosis by Alcohol
Drinking Habits.















Q1 (<4.4) 646 201 1.00 294 83 1.00
Q2 (4.4–6.9) 646 197 0.83 (0.55–1.26) 361 99 0.98 (0.67–1.42)
Q3 (6.9–10.5) 655 209 0.78 (0.46–1.33) 430 131 1.02 (0.54–1.94)
Q4 (≥10.5) 721 220 0.49 (0.27–0.89) 0.016 509 131 0.60 (0.32–1.13) 0.06
Retinol (µg/day)
Q1 (<161.0) 777 229 1.00 449 117 1.00
Q2 (161.0–333.0) 681 214 1.08 (0.72–1.60) 412 117 1.13 (0.70–1.83)
Q3 (333.0–561.0) 613 191 0.92 (0.48–1.74) 385 112 0.63 (0.41–0.97)
Q4 (≥561.0) 597 193 1.02 (0.59–1.77) 0.95 348 98 0.76 (0.34–1.69) 0.38
Vitamin D (µg/day) b
Q1 (<1.7) 707 208 1.00 440 105 1.00
Q2 (1.7–4.8) 619 189 1.22 (0.79–1.90) 407 108 0.70 (0.37–1.31)
Q3 (4.8–13.3) 478 150 0.89 (0.54–1.44) 305 102 1.11 (0.65–1.91)
Q4 (≥13.3) 864 280 0.92 (0.57–1.50) 0.47 442 129 1.15 (0.63–2.11) 0.28
β-Carotene (µg/day)
Q1 (<217.0) 560 165 1.00 275 72 1.00
Q2 (217.0–615.0) 597 204 1.08 (0.72–1.61) 375 116 1.54 (0.87–2.71)
Q3 (615.0–1924.5) 722 236 1.36 (0.89–2.08) 447 136 1.19 (0.76–1.86)
Q4 (≥1924.5) 789 222 0.78 (0.54–1.14) 0.007 497 120 1.13 (0.62–2.08) 0.47
Total carotenoids
(µg/day)
Q1 (<1429.5) 609 200 1.00 303 81 1.00
Q2 (1429.5–4380.5) 630 179 0.92 (0.55–1.54) 381 115 1.49 (1.06–2.10)
Q3 (4380.5–10563.0) 689 218 0.93 (0.50–1.74) 415 114 0.95 (0.42–2.18)
Q4 (≥10563.0) 740 230 0.91 (0.67–1.23) 0.66 495 134 1.36 (0.67–2.79) 0.62
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T1 (<5.3) 211 54 1.00 126 29 1.00
T2 (5.3–9.5) 193 46 0.94 (0.52–1.71) 129 31 0.92 (0.37–2.30)
T3 (≥9.5) 206 45 0.37 (0.18–0.73) 0.003 141 24 0.61 (0.24–1.56) 0.29
Retinol (µg/day)
T1 (<135.2) 198 44 1.00 132 22 1.00
T2 (135.2–364.2) 185 47 1.15 (0.78–1.69) 145 43 1.10 (0.55–2.19)
T3 (≥364.2) 227 54 1.17 (0.68–2.01) 0.65 119 19 0.41 (0.11–1.44) 0.13
Vitamin D (µg/day) b
T1 (<1.5) 182 38 1.00 129 19 1.00
T2 (1.5–6.7) 195 47 0.74 (0.48–1.14) 137 32 1.25 (0.79–1.98)
T3 (≥6.7) 233 60 0.94 (0.49–1.83) 0.75 130 33 0.88 (0.30–2.59) 0.68
β-Carotene (µg/day)
T1 (<333.1) 208 46 1.00 129 23 1.00
T2 (333.1–1254.2) 183 51 1.02 (0.60–1.74) 138 37 2.07 (0.79–5.40)
T3 (≥554.8) 219 48 0.87 (0.41–1.87) 0.65 129 24 1.46 (0.72–2.99) 0.94
Total carotenoids
(µg/day)
T1 (<2009.8) 211 48 1.00 133 24 1.00
T2 (2009.8–7732.4) 189 52 1.47 (0.74–2.95) 141 38 1.74 (0.91–3.33)
T3 (≥7732.4) 210 45 0.80 (0.39–1.64) 0.22 122 22 2.07 (0.92–4.66) 0.13
Hispanic
participants α-Tocopherol (mg/day)
T1 (<5.6) 226 76 1.00 106 40 1.00
T2 (5.6–10.3) 200 65 1.18 (0.66–2.14) 130 57 2.62 (1.17–5.86)
T3 (≥10.3) 171 64 1.20 (0.77–1.87) 0.45 117 40 1.57 (0.85–2.89) 0.53
Retinol (µg/day)
T1 (<182.5) 194 68 1.00 114 43 1.00
T2 (182.5–427.8) 208 65 0.70 (0.40–1.22) 124 48 1.11 (0.49–2.52)
T3 (≥427.8) 195 72 0.95 (0.42–2.14) 0.76 115 46 1.63 (0.84–3.16) 0.11
Vitamin D (µg/day) b
T1 (<1.9) 191 67 1.00 102 36 1.00
T2 (1.9–6.2) 190 65 0.67 (0.35–1.25) 114 53 1.84 (0.70–4.81)
T3 (≥6.2) 216 73 0.91 (0.56–1.48) 0.73 137 48 0.72 (0.35–1.44) 0.08
β-Carotene (µg/day)
T1 (<554.8) 202 73 1.00 118 51 1.00
T2 (554.8–1836.6) 207 73 0.89 (0.44–1.81) 119 46 0.83 (0.48–1.44)
T3 (≥1836.6) 188 59 0.93 (0.52–1.66) 0.86 116 50 0.58 (0.30–1.13) 0.15
Total carotenoids
(µg/day)
T1 (<3464.6) 211 77 1.00 117 46 1.00
T2 (3464.6–10075.0)) 196 62 0.83 (0.47–1.46) 119 46 0.89 (0.40–1.97)
T3 (≥10075.0) 190 66 1.04 (0.57–1.90) 0.77 117 45 0.76 (0.25–2.34) 0.65
White
participants α-Tocopherol (mg/day)
T1 (<6.1) 370 126 1.00 197 54 1.00
T2 (6.1–10.2) 274 102 1.17 (0.73–1.89) 202 54 0.80 (0.39–1.65)
T3 (≥10.2) 274 91 0.56 (0.25–1.27) 0.11 211 62 0.51 (0.24–1.10) 0.09
Retinol (µg/day)
T1 (<246.2) 308 106 1.00 190 50 1.00
T2 (246.2–491.2) 266 101 0.83 (0.41–1.71) 207 54 0.64 (0.39–1.05)
T3 (≥491.2) 344 112 0.82 (0.37–1.81) 0.63 213 66 0.60 (0.25–1.46) 0.33
Vitamin D (µg/day) b
T1 (<2.9) 282 96 1.00 201 56 1.00
T2 (2.9–15.9) 284 109 1.24 (0.76–2.04) 227 60 0.70 (0.41–1.19)
T3 (≥15.9) 352 114 0.77 (0.40–1.48) 0.24 182 54 1.34 (0.63–2.85) 0.18
β-Carotene (µg/day)
T1 (<411.1) 375 129 1.00 188 53 1.00
T2 (411.1–1600.6) 296 111 1.81 (1.04–3.17) 194 58 1.23 (0.67–2.24)
T3 (≥1600.6) 247 79 0.81 (0.56–1.16) 0.01 228 59 1.14 (0.63–2.05) 0.90
Total carotenoids
(µg/day)
T1 (<3005.4) 375 128 1.00 181 53 1.00
T2 (3005.4–9489.2) 294 103 0.91 (0.45–1.86) 204 52 1.15 (0.45–2.90)
T3 (≥9489.2) 249 88 0.96 (0.58–1.58) 0.77 225 65 1.50 (0.53–4.04) 0.65
a Odds ratio (OR), 95% confidence interval (95%CI) and Ptrend values were estimated by logistic regression (Proc Survey Logistic). Analyses
were adjusted for age, sex, education, body mass index, smoking status, total energy intake, alcohol drinking habits, hepatitis B virus
infection, hepatitis C virus infection, history of diabetes and history of high blood pressure. For all participants, the model was additionally
adjusted for race/ethnicity; b Daily vitamin D intake includes vitamin D intake from diet and supplement.
Biomedicines 2021, 9, 1093 11 of 17
4. Discussion
Utilizing data from the recent NHANES cycle that had transient elastography mea-
sures available for objectively detecting hepatic steatosis, the current results suggest that
higher intake of dietary α-tocopherol was associated with lower odds of steatosis. The
protective association of dietary α-tocopherol with steatosis remained significant among
blacks and whites. When stratified by alcohol drinking habits, we also found dietary
intake of α-tocopherol was inversely associated with the disease among those classified as
never/rare/occasional drinkers for the overall study population as well as among blacks
who belonged to the “never/rare/occasional” category.
Oxidative stress is considered as one of the key mechanisms of hepatocellular damage
and pathogenesis of NAFLD [5–7,40,41]. Vitamin E, particularly α-tocopherol due to its anti-
oxidative properties has been well studied as a treatment for hepatic steatosis. Two well-
known randomized clinical trials, “Pioglitazone, Vitamin E, or Placebo for Nonalcoholic
Steatohepatitis’ (PIVENS) trial [42], and the “Treatment of NAFLD in Children” (TONIC)
trial [43] both demonstrated significant improvements in liver histology with vitamin
E treatment compared to placebo. In addition, a recent systematic review with meta-
analysis of randomized controlled trials with vitamin E treatment concluded that adjuvant
vitamin E therapy provides significant biochemical and histological improvements in
adult patients with NAFLD although the short trail durations limit the conclusion on
the safety and efficacy of proposed treatments [19]. Data from observational studies are
scarce. Several observational studies showed protective associations of dietary vitamin
E intake with NAFLD [44–47]. However, these studies had limited sample size and/or
less diverse study populations regarding race/ethnicity. Therefore, we assessed overall
and race/ethnicity-specific associations between dietary α-tocopherol intake and hepatic
steatosis using a representative sample of the US population with a large sample size.
Our results in the overall study population and in blacks and whites were in agreement
with previous randomized trials [19,42,43] and observational studies [44–47] showing
the potential protective effects of vitamin E (as α-tocopherol) in relation to NAFLD. In
particular, the protective association was more prominent in blacks. Meanwhile, Hispanics
had the highest prevalence of NAFLD [3,28] but we did not observe a significant association
between α-tocopherol and steatosis in this racial/ethnic group. In fact, the second tertile of
α-tocopherol intake had significantly higher odds of steatosis compared to the lowest tertile
among Hispanics, which warrants a further investigation in future studies. Furthermore,
research has suggested genetic variations may in part contribute to the racial/ethnic
differences in the prevalence of NAFLD [48–52]. For example, the PNPLA3 “G” risk
allele was found more common in Hispanics than other racial/ethnic groups [49–52], and
thereby may have an impact on NAFLD risk in Hispanics [49,53]. Thus, it would be
interesting for future studies to investigate whether genetic variations may also play a role
in racial/ethnic differences in repose to the potential beneficial effects of α-tocopherol on
steatosis as observed in the current study.
Increasing evidence suggests the importance of vitamin D as physiological regulator
beyond its classical role in bone and calcium homeostasis [54]. Results from observational
studies show patients with NAFLD had lower levels of serum 25-hydroxy-vitamin D
(25(OH)D, indicator for vitamin D status in the human body) compared to individuals
without NAFLD [22–25] including one recent study utilizing NHANES III (1988–1994)
that reported serum 25(OH)D levels were independently and inversely associated with
severity of NAFLD [25]. In our study, we did not observe significant associations between
dietary vitamin D intake (vitamin D from diet and supplement) and steatosis among all
participants as well as participants stratified by race/ethnicity. In human body the majority
(90%) of vitamin D is derived from cutaneous conversion of 7-dehydrocholesterol to vitamin
D3 through exposure to sunlight and only about 10% is from dietary intake [54]. This
may in part explain the discrepancies in the results between serum and dietary vitamin
D in relation to NAFLD, that is, NAFLD was associated with lower serum vitamin D
concentrations as suggested by previous studies but not related to dietary vitamin D intake
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observed in our study. That said, consuming an adequate amount of vitamin D from
diet and/or supplement is nevertheless relevant for high-risk populations, for example
blacks and Hispanics among whom high prevalence of vitamin D deficiency has been
reported [55]. In fact, we observed Hispanics had the lowest vitamin D intake (from diet
and supplement) (12.6 ± 0.7 µg/day) among the racial/ethnic groups in the current study;
the value was more than two-fold lower compared to whites (27.2 ± 3.3 µg/day).
Healthful eating patterns, including high fruit and vegetable consumption, have been
associated with decreased risk for metabolic diseases and overall improved health [56].
Because of this, it is hypothesized that healthful dietary intake could also have protective
effects on the development and progression of NAFLD. Carotenoids are naturally occurring
pigments found in various fruits and vegetables, plants, algae and bacteria [57]. Thus,
higher levels of dietary carotenoids may suggest that a person has consumed an adequate
amount of fruits and vegetables [8,9]. Limited studies have assessed the potential protec-
tive effects of various carotenoids on NAFLD. Using NHANES, Christensen et al. found
levels of dietary and serum carotenoids such as α-carotene, β-carotene, β-cryptoxanthin,
and lutein/zeaxanthin were inversely associated with the odds of NAFLD [13]. Among
carotenoids, β-carotene is the most abundant carotenoid in the liver and has the highest pro-
vitamin A activity [57,58]. Experimental research has demonstrated the protective effects of
β-carotene on NAFLD in rats [59]. In humans, studies found lower serum β-carotene levels
or β-carotene to retinol ratio were associated with severity of NAFLD [60,61] while high
β-carotene concentrations were associated with improvement of the condition [62]. In our
study we did not observe significant associations overall or within individual racial/ethnic
groups for dietary total carotenoids. However, we observed a trend with higher β-carotene
intake and lower odds of steatosis for all participants without stratifications and partic-
ipants who were classified as never, rare or occasional alcohol drinkers. Similar trend
was also observed for white participants who belonged to the “never/rare/occasional
drinkers” category although there appeared a threshold effect with odds of steatosis being
higher for the second versus the lowest tertile of β-carotene intake. No associations were
found between dietary retinol (vitamin A) intake and steatosis. Although future research
is necessary to fully investigate the potential protective effects of β-carotene on steatosis
and the optimum range of intake of this nutrient needs to be established since high dosage
of β-carotene intake was linked to increased incidence of cancer and mortality [63,64],
the current results and findings from previous studies confirm the recommendation for
promoting dietary consumption of antioxidants such as β-carotene and other carotenoids
through fruits and vegetables.
In our study, we observed dietary α-tocopherol intake was inversely associated with
odds of steatosis among those who classified as never, rare or occasional alcohol drinkers
for the overall study population as well as for black participants who never, rarely or
occasionally drank alcohol. However, a similar but weaker pattern of association was
also observed among those who drank alcohol more frequently (sometimes/frequent
drinkers) although the results did not reach statistical significance possibly due to the
smaller number of participants in this category (sometimes/frequent drinkers: N = 1594
vs. never/rare/occasional drinkers: N = 2668). Also, we did not observe interactions
between alcohol drinking habits and α-tocopherol intake in relation to steatosis (p > 0.05).
In addition, we found a trend suggesting higher dietary β-carotene intake with lower odds
of steatosis among never, rare or occasional alcohol drinkers for the overall population and
whites. The NHANES self-report alcohol behavior questionnaire assessed the frequency
of alcohol drinking. There was no information regarding the exact amount of alcohol an
individual consumed each time, which may cause misclassification when categorizing
participants solely based upon how frequently one drank alcohol beverages. Therefore,
the above results need to be confirmed in future studies with detailed information on
individuals’ alcohol consumption.
One thing that needs to be noticed from our study is that the protective associa-
tions between dietary α-tocopherol intake and steatosis were consistent among black
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participants, suggesting the effects of vitamin E (as α-tocopherol) on NAFLD maybe
race/ethnicity-specific with more promising results observed in blacks. The possible
explanation could be blacks maybe more susceptible to α-tocopherol treatment. Using
NHANES 1999 to 2000, a pervious study reported African-Americans had the lowest serum
α-tocopherol levels among all the racial/ethnic groups (African-Americans, Mexican-
Americans and whites) examined [65]. We found dietary α-tocopherol intake was also
lower in blacks (8.9 ± 0.3 mg/day) than that in whites (9.6 ± 0.3 mg/day) and Hispanics
(9.3 ± 0.3 mg/day). Conversely, the potential beneficial effect of α-tocopherol on steatosis
was nevertheless found in blacks. Interestingly, we also observed blacks with steatosis had
higher HS-CRP (indicator for systemic inflammation) levels (7.7 ± 0.5 mg/L) compared
to their counterparts in other racial/ethnic groups (Hispanics: 4.6 ± 0.3 mg/L; whites:
5.5 ± 0.4 mg/L). Inflammation has been linked to NAFLD [66,67] and the progression to
more severe liver conditions such as cirrhosis and caner [68]. Thus, it would be interesting
and meaningful for future studies to elucidate the interrelationships and mechanisms
between α-tocopherol, inflammation and steatosis among blacks. The 2017–2018 NHANES
cycle does not have information on supplement vitamin E intake. Therefore, it is uncertain
whether blacks also had lower dietary vitamin E supplementation compared to other
racial/ethnic groups. However, one study using NHANES 2009–2012 revealed differential
use of dietary supplements across racial/ethnic groups with blacks (40%) and Hispanics
(36%) having lower prevalence of supplement use compared to whites (61%) [69]. In the
current study using NHANES 2017–2018, we also observed a lower percentage of blacks
(47.4%) who reported taking supplements (any kind) relative to whites (61.9%). Further
studies focusing on blacks are needed to confirm our results and identify optimum intake
range of vitamin E for this racial/ethnic group. In addition, detailed dietary information
on vitamin E consumption including intake of α-tocopherol from both diet and supple-
ment and different forms (e.g., α-tocopherol vs. γ-tocopherol) and sources of tocopherols
(e.g., natural products vs. synthetic compounds) should be collected when assessing
relationships between vitamin E and steatosis.
To our knowledge, the current study was the first to investigate both overall and
race/ethnicity-specific relations between dietary intakes of lipid-soluble micronutrients
and hepatic steatosis using a representative sample of the U.S. population. The strengths
of this study included using NHANES data with nationally representative samples and
a relatively large number of adults with ultrasound transient elastography examination,
providing the power to detect weaker associations. Additionally, our study utilized the
liver ultrasound transient elastography which is considered as a more objective measure
for hepatic steatosis [31]. Our study had several limitations. First, due to the nature of
cross-sectional studies, the temporal sequences may not be clear. Second, although the
transient elastography measurement is a widely used non-invasive method to assess liver
steatosis [35–37], it can be limited by fatness of a patient, the presence of perihepatic ascites,
and limited selection of an appropriate sampling area [70]. Third, misclassification may
have occurred in the analyses since there is no well-defined cutoff for steatosis utilizing the
transient elastography measurement. However, the cutoff (302 dB/m) used in our study
was recommended by Eddowes et al. who established this value using liver biopsy, which
is considered the gold standard for NAFLD diagnosis [38]. The 24-h dietary recall used in
NHANES has been extensively evaluated [32]; however, self-reported dietary recall is likely
to have both random and systematic errors [71], and a one-time, 24-h dietary recall may
not capture long-term dietary exposures. Further, our analyses did not include 24-h dietary
supplement intake (except for vitamin D) as there were no available data on supplements
such as α-tocopherol, retinol and most of the carotenoids for that day. However, further
adjustment for participants’ overall supplement intake status (taking supplement: yeas
or no) did not change the results substantially. Lastly, due to the unavailability of data
on circulating lipid-soluble micronutrients in the 2017–2018 NHANES cycle, we did not
further assess the associations of serum concentrations of lipid-soluble micronutrients with
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steatosis, which would provide a more complete picture for understanding the relationships
between micronutrients and NAFLD.
5. Conclusions
In the current study, dietary intake of α-tocopherol was inversely associated with odds
of hepatic steatosis. The inverse association remained significant among blacks and whites.
After stratification by individuals’ alcohol drinking habits, higher dietary α-tocopherol
intake was associated with lower odds of steatosis among those who were classified as
never, rare, or occasional alcohol drinkers for the overall study population as well as for
black participants. In addition, there was a trend suggesting higher β-carotene intake
with lower odds of steatosis. No significant associations were observed for other dietary
lipid-soluble micronutrients (retinol, vitamin D, total carotenoids) in relation to steatosis.
Our results suggest a potential protective effect of dietary vitamin E as α-tocopherol on
hepatic steatosis particularly among blacks. Due to the cross-sectional natural of the study
design, our results especially the unique findings between dietary α-tocopherol intake and
steatosis among blacks should be confirmed by prospective cohorts and randomized trials
in the future.
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